ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2021. The put-call ratio across all filers is 1.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $10,000 | -58.3% | 10,033 | -41.6% | 0.00% | – |
Q2 2023 | $24,000 | -33.3% | 17,173 | -22.7% | 0.00% | – |
Q1 2023 | $36,000 | -70.2% | 22,228 | +14.7% | 0.00% | – |
Q4 2022 | $121,000 | +1110.0% | 19,377 | +1120.2% | 0.00% | – |
Q3 2022 | $10,000 | +42.9% | 1,588 | +40.0% | 0.00% | – |
Q2 2022 | $7,000 | -63.2% | 1,134 | -73.8% | 0.00% | – |
Q1 2022 | $19,000 | -34.5% | 4,323 | -25.5% | 0.00% | – |
Q4 2021 | $29,000 | -56.7% | 5,800 | +1.8% | 0.00% | – |
Q3 2021 | $67,000 | -52.1% | 5,699 | -13.0% | 0.00% | – |
Q2 2021 | $140,000 | +29.6% | 6,550 | +70.1% | 0.00% | – |
Q1 2021 | $108,000 | +1.9% | 3,851 | -5.2% | 0.00% | – |
Q4 2020 | $106,000 | +23.3% | 4,061 | +75.8% | 0.00% | – |
Q3 2020 | $86,000 | -33.8% | 2,310 | -9.4% | 0.00% | – |
Q2 2020 | $130,000 | +64.6% | 2,549 | +1.7% | 0.00% | – |
Q1 2020 | $79,000 | -72.5% | 2,507 | -47.8% | 0.00% | – |
Q4 2019 | $287,000 | +245.8% | 4,801 | +109.9% | 0.00% | – |
Q3 2019 | $83,000 | -39.4% | 2,287 | -22.2% | 0.00% | – |
Q2 2019 | $137,000 | +59.3% | 2,938 | +38.1% | 0.00% | – |
Q1 2019 | $86,000 | -10.4% | 2,127 | +2.6% | 0.00% | – |
Q4 2018 | $96,000 | -82.3% | 2,073 | -83.0% | 0.00% | – |
Q3 2018 | $541,000 | +4.2% | 12,179 | -8.0% | 0.00% | – |
Q2 2018 | $519,000 | +464.1% | 13,235 | +939.7% | 0.00% | – |
Q1 2018 | $92,000 | +4.5% | 1,273 | -4.8% | 0.00% | – |
Q4 2017 | $88,000 | -45.0% | 1,337 | -58.0% | 0.00% | – |
Q3 2017 | $160,000 | +233.3% | 3,183 | +208.1% | 0.00% | – |
Q2 2017 | $48,000 | -40.0% | 1,033 | -54.5% | 0.00% | – |
Q1 2017 | $80,000 | -14.0% | 2,270 | -69.2% | 0.00% | – |
Q4 2016 | $93,000 | -6.1% | 7,376 | +4.0% | 0.00% | – |
Q3 2016 | $99,000 | +70.7% | 7,090 | +22.5% | 0.00% | – |
Q2 2016 | $58,000 | -43.1% | 5,790 | -4.1% | 0.00% | – |
Q1 2016 | $102,000 | -28.7% | 6,040 | -5.7% | 0.00% | – |
Q4 2015 | $143,000 | +23.3% | 6,405 | +30.3% | 0.00% | – |
Q3 2015 | $116,000 | -74.8% | 4,916 | -12.8% | 0.00% | – |
Q2 2015 | $461,000 | +308.0% | 5,640 | +362.3% | 0.00% | – |
Q1 2015 | $113,000 | -85.7% | 1,220 | -93.8% | 0.00% | -100.0% |
Q4 2014 | $792,000 | +2229.4% | 19,600 | +771.1% | 0.00% | – |
Q1 2014 | $34,000 | +9.7% | 2,250 | 0.0% | 0.00% | – |
Q4 2013 | $31,000 | +14.8% | 2,250 | +60.7% | 0.00% | – |
Q3 2013 | $27,000 | – | 1,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |